Simris Alg AB (publ) (SIMRIS-B.ST)
SEK 0.09
(0.21%)
SEK 0.09
(0.21%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -37.3 Million SEK | -52.75% |
| 2022 | -24.42 Million SEK | 13.87% |
| 2021 | -28.35 Million SEK | -10.75% |
| 2020 | -25.6 Million SEK | 4.86% |
| 2019 | -26.91 Million SEK | -12.27% |
| 2018 | -23.97 Million SEK | -4.32% |
| 2017 | -22.97 Million SEK | -18.76% |
| 2016 | -19.34 Million SEK | -63.87% |
| 2015 | -11.8 Million SEK | -39.71% |
| 2014 | -8.45 Million SEK | -113.93% |
| 2013 | -3.95 Million SEK | -37.89% |
| 2012 | -2.86 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -9.14 Million SEK | 4.52% |
| 2024 Q2 | -9.42 Million SEK | -3.05% |
| 2023 Q1 | -9.63 Million SEK | -3.65% |
| 2023 Q3 | -7.57 Million SEK | 28.01% |
| 2023 Q2 | -10.51 Million SEK | -9.11% |
| 2023 FY | -37.3 Million SEK | -52.75% |
| 2023 Q4 | -9.57 Million SEK | -26.51% |
| 2022 FY | -24.42 Million SEK | 13.87% |
| 2022 Q2 | -5.11 Million SEK | -26.76% |
| 2022 Q3 | -5.97 Million SEK | -16.98% |
| 2022 Q4 | -9.3 Million SEK | -55.54% |
| 2022 Q1 | -4.03 Million SEK | -11.07% |
| 2021 Q3 | -10.67 Million SEK | -47.78% |
| 2021 Q1 | -6.82 Million SEK | 12.91% |
| 2021 Q2 | -7.22 Million SEK | -5.77% |
| 2021 FY | -28.35 Million SEK | -10.75% |
| 2021 Q4 | -3.63 Million SEK | 65.99% |
| 2020 Q1 | -6.48 Million SEK | 6.62% |
| 2020 FY | -25.6 Million SEK | 4.86% |
| 2020 Q3 | -5.14 Million SEK | 16.14% |
| 2020 Q2 | -6.13 Million SEK | 5.41% |
| 2020 Q4 | -7.84 Million SEK | -52.43% |
| 2019 Q4 | -6.94 Million SEK | 2.2% |
| 2019 Q3 | -7.1 Million SEK | 9.84% |
| 2019 Q2 | -7.87 Million SEK | -57.84% |
| 2019 Q1 | -4.99 Million SEK | 23.18% |
| 2019 FY | -26.91 Million SEK | -12.27% |
| 2018 Q1 | -5.66 Million SEK | 12.41% |
| 2018 Q3 | -6.52 Million SEK | -23.46% |
| 2018 Q4 | -6.49 Million SEK | 0.46% |
| 2018 FY | -23.97 Million SEK | -4.32% |
| 2018 Q2 | -5.28 Million SEK | 6.66% |
| 2017 FY | -22.97 Million SEK | -18.76% |
| 2017 Q4 | -6.46 Million SEK | -11.9% |
| 2017 Q3 | -5.77 Million SEK | -12.94% |
| 2017 Q2 | -5.11 Million SEK | 8.94% |
| 2017 Q1 | -5.61 Million SEK | 16.78% |
| 2016 Q1 | -4.79 Million SEK | -51.39% |
| 2016 Q2 | -4.39 Million SEK | 8.34% |
| 2016 Q3 | -3.39 Million SEK | 22.73% |
| 2016 FY | -19.34 Million SEK | -63.87% |
| 2016 Q4 | -6.75 Million SEK | -98.62% |
| 2015 Q2 | -3.59 Million SEK | -31.11% |
| 2015 Q3 | -2.3 Million SEK | 36.02% |
| 2015 Q4 | -3.17 Million SEK | -37.83% |
| 2015 Q1 | -2.74 Million SEK | 0.0% |
| 2015 FY | -11.8 Million SEK | -39.71% |
| 2014 FY | -8.45 Million SEK | -113.93% |
| 2013 FY | -3.95 Million SEK | -37.89% |
| 2012 FY | -2.86 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Asarina Pharma AB (publ) | -12.82 Million SEK | -190.809% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 88.003% |
| NextCell Pharma AB | -41.95 Million SEK | 11.094% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -127.498% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 90.39% |
| AcouSort AB (publ) | -17.08 Million SEK | -118.298% |
| OncoZenge AB (publ) | -15.9 Million SEK | -134.593% |
| Xintela AB (publ) | -54.08 Million SEK | 31.023% |
| Ziccum AB (publ) | -21.41 Million SEK | -74.225% |
| Active Biotech AB (publ) | -45.8 Million SEK | 18.548% |
| Alzinova AB (publ) | -16.48 Million SEK | -126.365% |
| Amniotics AB (publ) | -30.87 Million SEK | -20.845% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 84.993% |
| BioArctic AB (publ) | 229.24 Million SEK | 116.273% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 91.998% |
| Camurus AB (publ) | 431.44 Million SEK | 108.647% |
| Cantargia AB (publ) | -280.02 Million SEK | 86.678% |
| Scandinavian ChemoTech AB (publ) | -21.09 Million SEK | -76.876% |
| CombiGene AB (publ) | -35.66 Million SEK | -4.597% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 75.433% |
| Genovis AB (publ.) | 61.5 Million SEK | 160.659% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 67.081% |
| Mendus AB (publ) | -101.61 Million SEK | 63.289% |
| Isofol Medical AB (publ) | -37.07 Million SEK | -0.631% |
| Kancera AB (publ) | -64.88 Million SEK | 42.51% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 792.629% |
| LIDDS AB (publ) | -40.2 Million SEK | 7.215% |
| Lipum AB (publ) | -37.17 Million SEK | -0.342% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -207.594% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 406.558% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -108.443% |
| Saniona AB (publ) | -95.81 Million SEK | 61.064% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 79.237% |
| Intervacc AB (publ) | -102.85 Million SEK | 63.729% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -8417.123% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -125.776% |
| Corline Biomedical AB | -1.8 Million SEK | -1962.189% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 79.023% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 34.346% |
| Aptahem AB (publ) | -11.11 Million SEK | -235.692% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 69.687% |
| Fluicell AB (publ) | -26.55 Million SEK | -40.487% |
| Biovica International AB (publ) | -124.82 Million SEK | 70.114% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 11.648% |
| Abliva AB (publ) | -95.5 Million SEK | 60.941% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 88.588% |
| 2cureX AB (publ) | -32.51 Million SEK | -14.721% |
| I-Tech AB | 20.2 Million SEK | 284.651% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 95.515% |
| Cyxone AB (publ) | -22.98 Million SEK | -62.273% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 59.185% |
| Biosergen AB | -27.03 Million SEK | -37.978% |
| Nanologica AB (publ) | -75.15 Million SEK | 50.364% |
| SynAct Pharma AB | -215.81 Million SEK | 82.714% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 15.32% |
| BioInvent International AB (publ) | -330.3 Million SEK | 88.706% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | -57.16% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 85.025% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -275.679% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 65.865% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -219.447% |